Werewolf Therapeutics, Inc. (HOWL) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.
The consensus price target is $1.00, representing an upside of 9% from the current price $0.92.
Analysts estimate Earnings Per Share (EPS) of $-1.50 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.63 vs est $-1.50 (missed -8.9%). 2025: actual $-1.32 vs est $-1.51 (beat +12.3%). Analyst accuracy: 89%.
HOWL Stock — 12-Month Price Forecast
$1.00
▲ +8.99% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Werewolf Therapeutics, Inc., the price target is $1.00.
The average price target represents a +8.99% change from the last price of $0.92.
HOWL Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Werewolf Therapeutics, Inc. in the past 3 months
EPS Estimates — HOWL
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.63
vs Est –$1.50
▼ 8.2% off
2025
Actual –$1.32
vs Est –$1.51
▲ 14.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — HOWL
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.002B
vs Est $0.002B
▲ 0.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
